Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
- Conditions
- Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03784326
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3040
- Registration Number
- NCT03782207
- Locations
- 🇬🇧
St James Hospital; Dept of Oncology/Hematology, Leeds, United Kingdom
🇪🇸Hospital Universitario Infanta Cristina; Servicio de Oncologia, Badajoz, Spain
🇬🇧Clatterbridge Cancer Centre, Bebington, United Kingdom
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- Procedure: Biopsy of BladderDrug: AtezolizumabDrug: CisplatinProcedure: Computed TomographyProcedure: CystoscopyDrug: GemcitabineDrug: FluorouracilProcedure: Magnetic Resonance ImagingDrug: MitomycinOther: Quality-of-Life AssessmentRadiation: Radiation TherapyOther: Survey AdministrationProcedure: Transurethral Resection of Bladder Tumor
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 475
- Registration Number
- NCT03775265
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Henry Ford Saint John Hospital - Macomb Medical, Macomb, Michigan, United States
🇺🇸Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03768063
- Locations
- 🇺🇸
Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States
🇺🇸HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 1000
- Registration Number
- NCT03767075
- Locations
- 🇮🇹
Instituto Nazionale dei Tumori di Milano, Milano, Italy
🇬🇧Cancer Research UK Cambridge Centre, Cambridge, United Kingdom
🇩🇪Deutsches Krebsforschungszentrum (NCT/DKFZ), Heidelberg, Baden-Wurtemberg, Germany
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 401
- Registration Number
- NCT03762018
- Locations
- 🇧🇪
CHU Liege, Liege, Belgium
🇫🇷Le Mans - CHG, Le Mans, France
🇨🇭Kantonsspital Aarau, Aarau, Switzerland
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 837
- Registration Number
- NCT03755791
- Locations
- 🇺🇸
Exelixis Clinical Site #88, Philadelphia, Pennsylvania, United States
🇦🇺Exelixis Clinical Site #78, Camperdown, New South Wales, Australia
🇺🇸Exelixis Clinical Site #7, Burlington, Massachusetts, United States
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 284
- Registration Number
- NCT03756298
- Locations
- 🇰🇷
Korea University, Guro hospital, Seoul, Korea, Republic of
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
- Conditions
- Stage II Cervical Cancer AJCC v8Cervical AdenocarcinomaCervical Squamous Cell CarcinomaStage IVA Cervical Cancer AJCC v8Cervical Adenosquamous CarcinomaStage IIA Cervical Cancer AJCC v8Stage IIA2 Cervical Cancer AJCC v8Stage IIB Cervical Cancer AJCC v8Stage IB2 Cervical Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT03738228
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Nabil Adra
- Target Recruit Count
- 6
- Registration Number
- NCT03737123
- Locations
- 🇺🇸
Nebraska Methodist Hosptial, Omaha, Nebraska, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.